List of Excipients in Branded Drug DICLOFENAC

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
TriVue Pharmaceuticals Inc	DICLOFENAC	diclofenac	73480-242	CELLULOSE, MICROCRYSTALLINE	2030-04-23
TriVue Pharmaceuticals Inc	DICLOFENAC	diclofenac	73480-242	CROSCARMELLOSE SODIUM	2030-04-23
TriVue Pharmaceuticals Inc	DICLOFENAC	diclofenac	73480-242	FD&C BLUE NO. 1	2030-04-23

Generic Drugs Containing DICLOFENAC

Company	Ingredient	NDC	Excipient
Akorn	diclofenac sodium	17478-892	BORIC ACID
Akorn	diclofenac sodium	17478-892	EDETATE DISODIUM
Akorn	diclofenac sodium	17478-892	POLYOXYL 35 CASTOR OIL

What are the Most Frequently-Used Excipients in DICLOFENAC?

# Of NDCs	Excipient
2	BORIC ACID
2	EDETATE DISODIUM
2	POLYOXYL 35 CASTOR OIL

Diclofenac Excipient Strategy and Commercial Opportunities

Last updated: August 2, 2026

Diclofenac is a mature, highly commoditized NSAID with extensive generic competition. The strongest commercial opportunities are not in the active ingredient itself, but in excipient-enabled delivery systems that improve solubility, skin penetration, local exposure, tolerability, dosing convenience, or product stability. The most attractive platforms are topical gels, sprays, patches, ophthalmic solutions, oral liquids, modified-release tablets, and low-irritancy oral formulations.

What excipient strategies are most valuable for diclofenac?

Excipient selection should address diclofenac’s low aqueous solubility, salt-dependent dissolution, gastrointestinal tolerability, local delivery requirements, and chemical stability.

Diclofenac is a weak acid. Diclofenac sodium and diclofenac potassium provide different dissolution and absorption profiles, while diclofenac free acid is used in several topical systems. Product performance depends heavily on pH, solvent selection, surfactants, penetration enhancers, polymer rheology, particle size, and packaging.

Product objective	Relevant excipient strategy	Commercial value
Faster oral dissolution	Alkalinizing agents, wetting agents, micronized API, porous carriers	Supports rapid-onset tablets, capsules, and liquids
Sustained oral exposure	Hydrophilic or hydrophobic matrix polymers, multiparticulates, coating systems	Differentiates modified-release products
Topical skin penetration	Ethanol, propylene glycol, isopropyl alcohol, oleic acid derivatives, phospholipids, surfactants	Supports gels, sprays, creams, and foams
Reduced skin residue	Volatile solvents, low-tack polymers, optimized emulsion systems	Improves patient acceptance
Improved ophthalmic delivery	Cyclodextrins, solubilizers, buffers, tonicity agents, viscosity modifiers	Enables clear, stable eye-drop products
Localized prolonged delivery	Adhesive polymers, pressure-sensitive adhesives, permeation enhancers	Supports patches and extended-wear systems
Reduced GI exposure	Enteric coatings, delayed-release polymers, local-release systems	Enables oral products with differentiated tolerability claims
Better stability	Chelators, antioxidants, pH control, oxygen-barrier packaging	Reduces degradation and extends shelf life

The commercial value of an excipient is highest when it changes a clinically relevant product attribute rather than merely replacing a low-cost inactive ingredient.

What diclofenac dosage forms create the largest excipient opportunities?

Topical gels and solutions

Topical diclofenac is the most developed excipient-driven segment. FDA-approved products include diclofenac sodium topical gel and diclofenac sodium topical solution, while other markets contain diclofenac diethylamine, diclofenac epolamine, and related topical salts.

Typical topical systems use combinations of:

• Water and alcohol solvents
• Propylene glycol or polyethylene glycol
• Carbomer or other acrylic polymers
• Hydroxyethylcellulose and related viscosity modifiers
• Surfactants and solubilizers
• pH adjusters
• Preservatives
• Skin-conditioning agents

Voltaren Arthritis Pain, an over-the-counter diclofenac sodium topical gel, contains diclofenac sodium at 1% and uses a hydroalcoholic gel platform. The product is labeled for temporary relief of arthritis pain in selected joints and carries a four-times-daily application regimen in the United States.[1]

The principal formulation challenge is balancing diclofenac solubilization with skin permeation. Excessive solvent or surfactant loading can increase irritation, dryness, odor, or residue. High polymer loading can reduce spreadability and drug release. A commercially viable formulation must therefore optimize drug release, dermal flux, drying time, tack, washability, and packaging compatibility.

Oral immediate-release and modified-release products

Diclofenac potassium is used in immediate-release tablets and oral solution products. Diclofenac sodium is used in delayed-release and extended-release tablets. The two salts are not interchangeable from a formulation or regulatory perspective.

Common oral excipient functions include:

• Microcrystalline cellulose and other fillers
• Crospovidone, croscarmellose sodium, or sodium starch glycolate as disintegrants
• Povidone or hypromellose as binders
• Magnesium stearate or alternative lubricants
• Colloidal silicon dioxide as a glidant
• Film-coating polymers
• Methacrylate or cellulose-based enteric polymers
• Buffers and alkalinizing agents

Immediate-release products compete primarily on price, availability, dose strength, and supply reliability. Excipient innovation is more defensible in modified-release tablets, liquid formulations, orally disintegrating tablets, and products designed for rapid onset.

Extended-release diclofenac formulations face a difficult commercial equation. The product must maintain release control despite diclofenac’s dose, pH-dependent solubility, and gastrointestinal transit variability. A matrix system that is simple to manufacture may have limited intellectual-property value unless it produces a measurable pharmacokinetic or tolerability advantage.

Ophthalmic solutions

Diclofenac ophthalmic products require a clear, sterile, stable solution or suspension. The principal formulation constraints are ocular tolerability, sterility, particulate control, pH, osmolality, preservative exposure, and container performance.

Potential excipient platforms include:

• Cyclodextrins for solubilization
• Polysorbates and other nonionic surfactants
• Borate, phosphate, or citrate buffers
• Sodium chloride or other tonicity agents
• Hydroxypropyl methylcellulose or related viscosity modifiers
• Benzalkonium chloride in multidose preserved systems
• Preservative-free unit-dose packaging

Diclofenac sodium ophthalmic solution is used for postoperative ocular inflammation and pain in the United States. The FDA label identifies a 0.1% ophthalmic solution strength for approved products.[2] Preservative-free packaging and reduced ocular-surface irritation are potential differentiation paths, particularly for repeated dosing and patients with compromised ocular surfaces.

Transdermal patches

Diclofenac epolamine topical systems use adhesive matrices or related transdermal technologies. The principal excipient opportunity is not simply increasing drug loading. It is controlling:

• Adhesion during movement and perspiration
• Drug crystallization within the adhesive
• Skin irritation
• Wear time
• Moisture vapor transmission
• Peel strength
• Residual drug in the patch
• Release consistency across temperature conditions

A successful patch platform can command higher pricing than a conventional gel because it offers less frequent application and controlled local delivery. Manufacturing complexity and adhesive performance create greater barriers than those found in standard topical gels.

What formulation patents protect diclofenac products?

Diclofenac’s original active-ingredient patent protection is largely expired in major markets. The remaining IP value is concentrated in secondary patents and proprietary know-how.

Formulation patents

Formulation claims may cover:

• Specific solvent ratios
• Polymer systems
• Particle-size distributions
• Salt or polymorph selection
• Stabilizer combinations
• pH ranges
• Transdermal adhesive compositions
• Ophthalmic solubilization systems
• Preservative-free packaging
• Controlled-release coatings
• Manufacturing parameters that produce a defined microstructure

A formulation patent is stronger when the claimed composition produces a measurable technical effect, such as higher dermal delivery, lower crystallization, improved stability, reduced irritation, or a clinically meaningful pharmacokinetic profile.

Method-of-use patents

Diclofenac method-of-use patents may address:

• Osteoarthritis pain
• Acute musculoskeletal pain
• Postoperative ocular inflammation
• Migraine or acute pain indications
• Specific dosing schedules
• Administration to selected anatomical sites
• Reduced systemic exposure through topical administration

Method-of-use protection is commercially relevant only if the indication is still protected and the labeling strategy can prevent or constrain the competing product’s use. For a mature generic drug, skinny-label strategies can reduce the practical effect of method patents.

Manufacturing and process IP

Manufacturing barriers can be more durable than composition claims. Relevant process areas include:

• Preparation of stable diclofenac dispersions
• Control of particle size and polymorphic form
• Homogenization of topical gels
• Coating and drying of transdermal systems
• Sterile filling of ophthalmic solutions
• Control of residual solvents
• Prevention of API crystallization
• Container-closure compatibility

Process patents are difficult to enforce against a competitor without access to manufacturing records. Their commercial value often lies in yield, quality, scale-up, and regulatory reproducibility rather than litigation alone.

When does diclofenac lose exclusivity?

Diclofenac as an active ingredient has already lost primary market exclusivity in the United States and other major markets. Generic oral, topical, and ophthalmic products are widely available.

The relevant exclusivity question is product-specific:

Product type	Primary exclusivity position	Current commercial implication
Generic oral diclofenac sodium or potassium	Primary active-ingredient exclusivity expired	Price competition is intense
Generic delayed-release tablets	Product-specific patents and approvals largely mature	Manufacturing scale and supply reliability matter
Topical diclofenac gel	Brand formulation and OTC positioning remain differentiated	Generic and private-label pressure remains high
Topical diclofenac solution	Product-specific formulation and use claims may matter	Opportunity exists for alternative delivery systems
Diclofenac ophthalmic solution	Mature prescription market	Preservative-free and unit-dose systems can differentiate
Diclofenac epolamine patch	Delivery-system complexity creates more protection	Adhesive and wear-performance IP can support premium pricing
Diclofenac-misoprostol combination	Combination formulation and indication history matter	Generic substitution is constrained by product complexity

FDA Orange Book listings are specific to each approved prescription NDA. They can include patents covering drug composition, formulation, method of use, or other listed attributes. The Orange Book does not provide a single expiration date for “diclofenac” because different salts, strengths, dosage forms, and products have separate regulatory records.[3]

What is the Orange Book status of diclofenac products?

The Orange Book includes prescription diclofenac products and related combination products. Relevant reference-product categories include:

• Diclofenac sodium delayed-release tablets
• Diclofenac sodium extended-release tablets
• Diclofenac potassium immediate-release tablets
• Diclofenac sodium ophthalmic solution
• Diclofenac sodium topical products
• Diclofenac and misoprostol delayed-release tablets
• Diclofenac epolamine topical systems, where listed under the applicable reference product

Orange Book status must be assessed at the NDA and patent-list level. A product may have no unexpired listed patents while retaining commercial differentiation through brand recognition, OTC distribution, formulation know-how, or device and packaging performance.

For diligence, the relevant analysis is:

1. Identify the reference NDA.
2. Review active patent listings.
3. Separate formulation patents from method-of-use patents.
4. Check expiration dates and pediatric extensions.
5. Review approved generic strengths and dosage forms.
6. Determine whether a proposed label can omit protected uses.
7. Compare the proposed formulation against listed product characteristics.

Which companies are challenging diclofenac products?

Diclofenac is challenged primarily by generic-drug manufacturers rather than biosimilar developers. Major generic suppliers and contract manufacturers may compete in oral, topical, ophthalmic, and combination formats, depending on jurisdiction.

The competitive field includes:

• Large generic companies with multisource oral products
• Specialty topical manufacturers
• OTC private-label suppliers
• Transdermal patch developers
• Ophthalmic product manufacturers
• Regional pharmaceutical companies
• Contract development and manufacturing organizations

Paragraph IV litigation is product-specific. A generic applicant files a Paragraph IV certification when it asserts that an Orange Book-listed patent is invalid, unenforceable, or not infringed. Because diclofenac has multiple mature dosage forms, Paragraph IV exposure is most relevant to newer branded formulations, topical systems, combination products, and products with active secondary patents.[4]

A generic applicant may instead file a Paragraph III certification if it accepts that a listed patent remains valid and waits for expiration. For a mature molecule, the commercial decision often depends less on the active ingredient and more on whether the target product has a defensible formulation or delivery system.

What generic entry risks exist for diclofenac?

Generic entry risk is high for standard oral diclofenac products and moderate to high for conventional topical products.

High-risk categories

• Immediate-release tablets
• Delayed-release tablets with conventional excipients
• Standard ophthalmic solutions
• Basic topical gels
• Diclofenac sodium capsules or tablets

Moderate-risk categories

• Extended-release tablets
• Topical solutions with specialized solvent systems
• Combination products
• Products with device-dependent dosing
• Preservative-free ophthalmic systems

Lower-risk categories

• Patches with difficult adhesive and release requirements
• Products with strong clinical differentiation
• Formulations supported by dense, validated formulation patents
• Products requiring complex manufacturing controls or specialized packaging

A generic launch may follow one of four pathways:

Launch pathway	Timing	Commercial effect
First generic approval	Near patent or exclusivity expiry	Can create rapid price erosion
180-day exclusivity launch	First qualifying Paragraph IV applicant	May temporarily preserve generic margins
Later multisource entry	After first generic launch	Usually accelerates price decline
Authorized generic	Brand-controlled or licensed generic	Limits first-generic economics

How strong is the diclofenac patent estate?

The core diclofenac patent estate is weak because the molecule is old and widely genericized. The secondary estate can be moderate when it combines composition claims, clinical data, manufacturing know-how, and a differentiated dosage form.

Patent strength is highest when:

• The formulation uses a narrow and non-obvious excipient combination.
• The product demonstrates superior dermal flux or local exposure.
• The formulation prevents crystallization under accelerated conditions.
• The delivery system has measurable adherence or wear advantages.
• The product has a protected indication with meaningful prescription demand.
• The claims cover both composition and manufacturing steps.
• The formulation is difficult to design around without losing performance.

Patent strength is lower when:

• Claims cover conventional excipients at broad concentration ranges.
• The product has no demonstrated clinical advantage.
• The formulation can be replicated with common polymers and solvents.
• The product is interchangeable with numerous approved generics.
• The patent covers only a narrow use that can be omitted from a generic label.

What licensing deals could create commercial value?

Licensing opportunities are most credible around formulation platforms rather than diclofenac itself. A licensor could offer:

• A topical penetration-enhancement system
• A low-irritancy hydroalcoholic gel
• A sustained-release matrix technology
• A preservative-free ophthalmic platform
• A long-wear transdermal adhesive
• A spray or foam delivery system
• A co-crystal, amorphous dispersion, or particle-engineering process
• A manufacturing process that improves yield and batch consistency

Potential deal structures include:

• Upfront payment plus development milestones
• Regional licensing for prescription or OTC markets
• Supply agreements tied to proprietary excipients
• Co-development with a generic manufacturer
• Royalty-bearing formulation licenses
• Authorized-generic arrangements
• Private-label commercialization agreements

A platform license is more attractive when the excipient system can be applied to other poorly soluble NSAIDs or topical analgesics. Diclofenac alone may not justify a large development payment unless the formulation provides clear regulatory or commercial differentiation.

What FDA regulatory issues affect diclofenac excipient development?

FDA requirements differ by dosage form and regulatory pathway.

For an abbreviated new drug application, the formulation must generally demonstrate pharmaceutical equivalence and bioequivalence to the reference product. A change in excipient type or level can affect dissolution, absorption, local delivery, irritation, or product performance.

For topical products, regulatory risk includes:

• Comparative skin permeation
• In vitro release testing
• Local tolerability
• Residual solvents
• Microbial limits
• Preservative effectiveness
• Container compatibility
• Uniformity of delivered dose

For ophthalmic products, sterility, particulate control, preservative performance, pH, osmolality, and container-closure integrity are central. For OTC products, the formulation must comply with the applicable monograph or proceed through an NDA pathway, depending on the product and indication.[1,5]

Excipient regulatory risk is higher when a proposed ingredient lacks substantial prior use in the intended route, concentration, or dosage form. Novel excipients can increase development and review timelines, even when the API is well established.

What are the best commercial opportunities for diclofenac excipients?

Premium topical delivery

The strongest near-term opportunity is a topical product that improves application experience and supports premium positioning. Useful attributes include rapid drying, low tack, low odor, low staining, easy spreading, reduced application frequency, and reliable dosing.

Preservative-free ophthalmic products

Unit-dose or multidose preservative-free systems can target patients requiring repeated use or those with ocular-surface sensitivity. Packaging cost is higher, but the product may support a differentiated prescription or specialty-pharmacy position.

Long-wear patches

Patches can capture value through convenience, controlled exposure, and localized treatment. The main barriers are adhesive development, scale-up, device testing, and regulatory comparability.

Oral liquid and pediatric formats

Diclofenac oral liquids can address swallowing difficulty, dose flexibility, and institutional use. Flavor masking, sedimentation control, preservative strategy, and dosing-device accuracy determine commercial viability.

Combination products

Diclofenac-misoprostol products address NSAID-associated ulcer-risk concerns through combination therapy. The commercial opportunity is limited by regimen complexity, contraindications, tolerability, and generic competition, but formulation expertise can still matter.

How does diclofenac compare with competing NSAIDs?

Attribute	Diclofenac	Ibuprofen	Naproxen	Ketoprofen
Core market maturity	Very high	Very high	Very high	High
Topical opportunity	Strong	Strong	More limited in some markets	Strong in selected markets
Salt-driven formulation effects	Important	Important	Important	Important
Transdermal potential	Established	Established in some markets	More limited	Established in some markets
Oral generic price pressure	Severe	Severe	Severe	Severe
Excipient differentiation	Highest in topical, ophthalmic, patch formats	High in OTC and topical products	Moderate	High in topical products
Biosimilar exposure	None	None	None	None

Diclofenac’s commercial advantage is its broad history of use across oral, topical, ophthalmic, and transdermal products. Its disadvantage is intense competition and limited ability to protect the API itself.

What revenue exposure should investors and licensors consider?

Revenue exposure is concentrated in mature generic and OTC categories. Standard oral diclofenac products generally have low unit economics and depend on manufacturing scale, procurement contracts, and supply continuity.

Higher-value segments include:

• Branded topical OTC gels
• Prescription topical solutions
• Transdermal patches
• Specialty ophthalmic products
• Combination products
• Products with proprietary packaging or dosing devices

A formulation opportunity should be evaluated against five commercial metrics:

1. Expected price premium over standard generic diclofenac.
2. Incremental manufacturing cost from the excipient system.
3. Regulatory evidence required for approval.
4. Defensibility against a design-around formulation.
5. Size and persistence of the target patient segment.

Key Takeaways

• Diclofenac’s API patent protection is exhausted in major markets.
• Commercial value resides in formulation, delivery, packaging, and manufacturing IP.
• Topical gels, topical solutions, ophthalmic products, and patches offer the clearest excipient opportunities.
• Conventional oral tablets face severe generic price pressure.
• The most defensible excipient technologies improve measurable attributes such as dermal flux, stability, local tolerability, wear time, or dosing convenience.
• Paragraph IV risk is product-specific and depends on active Orange Book listings for the relevant NDA.
• Diclofenac has no biosimilar risk because it is a small-molecule NSAID.
• Licensing value is higher for a platform applicable to multiple topical or poorly soluble drugs than for a diclofenac-only technology.
• Manufacturing know-how can be commercially important even when composition patents are weak.

FAQs

Is diclofenac a good candidate for a novel excipient?

Yes, particularly for topical, ophthalmic, and transdermal products. A novel excipient must produce a clear performance benefit and carry an acceptable regulatory burden.

Which diclofenac salt is best for rapid oral delivery?

Diclofenac potassium is commonly used in immediate-release products, while diclofenac sodium is widely used in delayed-release and extended-release products. The optimal salt depends on the target dissolution and pharmacokinetic profile.

Can a diclofenac gel obtain new patent protection?

Yes. Protection may be available for a non-obvious solvent-polymer system, penetration-enhancement technology, stability solution, dosing device, or manufacturing process. The claims must distinguish the product from existing topical diclofenac formulations.

Are diclofenac topical products eligible for biosimilar competition?

No. Biosimilar pathways apply to biological products. Diclofenac products are small-molecule drugs and compete through generic-drug pathways.

What is the most scalable diclofenac formulation opportunity?

A topical hydroalcoholic gel, spray, or foam is generally more scalable than a transdermal patch or sterile ophthalmic system. The best opportunity depends on whether the commercial strategy prioritizes low manufacturing cost, premium pricing, or regulatory differentiation.

References

1. U.S. Food and Drug Administration. (2020). Voltaren Arthritis Pain topical gel: Drug facts label. FDA.
2. U.S. Food and Drug Administration. (2023). Diclofenac sodium ophthalmic solution prescribing information. FDA.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
4. U.S. Food and Drug Administration. (2024). Paragraph IV drug product applications: Patent certifications and litigation. FDA.
5. U.S. Food and Drug Administration. (2024). Inactive ingredient database. FDA.